Ricardo Kratje
Cofundador
BioSynaptica
BioSynaptica develops engineered biopharmaceuticals based on human erythropoietin (hEPO) to treat neurodegenerative diseases. Their proprietary technology modifies hEPO to retain neuroprotective and neuroplastic properties while removing erythropoietic side effects, offering a potential therapy to slow disease progression.
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Marcos Oggero
Cofundador
Milagros Bürgi
Cofundadora
Product
Problem
Neurodegenerative diseases currently lack effective treatments to halt their progression or cure the conditions. Existing therapeutic approaches often fail to address the underlying pathology, leading to continued patient decline and reduced quality of life.
Solution
BioSynaptica is developing novel biopharmaceuticals derived from human erythropoietin (hEPO) to address neurodegenerative diseases. Our proprietary technology modifies the hEPO molecule to retain its demonstrated neuroprotective and neuroplastic properties while eliminating its erythropoietic side effects. This engineered molecule offers a potential therapeutic avenue to slow or halt disease progression and improve patient outcomes for conditions such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
Target Audience
Our primary target audience includes pharmaceutical companies and research institutions focused on developing therapeutics for neurodegenerative and neurological disorders.
Features
- Engineered human erythropoietin (hEPO) molecule with preserved neuroprotective and neuroplastic activity.
- Elimination of undesirable erythropoietic side effects associated with native hEPO.
- Demonstrated in vivo efficacy in animal models of degenerative retinopathy.
- Extended blood residence time compared to native hEPO.
- Intellectual property protection secured with patents granted in key international markets.
- Ongoing development for preclinical trials in diabetic retinopathy and age-related macular degeneration models.